Study of Molecular Response Adaptive Immuno-Chemotherapy in Patients With NSCLC

Titre officiel

A Biomarker-Directed, Open Label, Multi-Centre Phase II Study of Molecular Response Adaptive Immuno-Chemotherapy in Patients With Non-Small Cell Lung Cancer

Sommaire:

L’objectif de la première étape de l’étude est de déterminer si l’on peut utiliser des tests sanguins pour voir comment le cancer répond au traitement par le pembrolizumab.

Description de l'essai

Primary Outcome:

  • Concordance rate between molecular response and radiologic response
Secondary Outcome:
  • Time to molecular response
  • Correlate molecular response to RECIST response based on changes in ctDNA levels
  • Correlate molecular response to progression-free survival based on changes in ctDNA levels
  • Correlate molecular response to overall survival based on changes in ctDNA levels
  • Explore the degree of ctDNA reduction with clinical outcomes assessed by measuring changes in ctDNA levels in plasma
The standard or usual treatment for this disease is pembrolizumab given by needle every three weeks. This study will be done in two stages. The purpose of stage 1 of the study is to find out if we can use blood tests to see how the cancer is responding to treatment with pembrolizumab. A second stage of the study will take place once stage 1 is completed. In stage 2 blood tests will be used to help determine if patients whose cancer does not seem to be getting better on treatment with pembrolizumab, would do better on a different treatment.

Voir cet essai sur ClinicalTrials.gov

Intéressé(e) par cet essai?

Imprimez cette page et apportez-la chez votre médecin pour discuter de votre admissibilité à cet essai et des options de traitement. Seul votre médecin peut vous recommander pour un essai clinique.

Ressources

Société canadienne du cancer

Ces ressources sont fournies en partenariat avec Société canadienne du cancer